Xbrane sets sales goals for ranibizumab biosimilar

Xbrane Biopharma has begun a phase 3 trial of its lead product Xlucane and announced a sales target for the biosimilar, according to a press release.

Xlucane, a ranibizumab (Lucentis, Novartis/Genentech) biosimilar, is being co-developed and commercialized with Stada Arzneimittel AG, and is expected to bring in revenue during the first quarter of 2022, the release said.

The company has set an annual net sales target of 350 million euros after the product launch.

“We strongly believe in the commercial prospects of Xlucane. There is a great need for more cost-efficient products in the ophthalmic VEGFa inhibitor market and I am confident that Xlucane will be received positively by the ophthalmology community and patients,” Xbrane CEO Martin Åmark said.

 

Xbrane Biopharma has begun a phase 3 trial of its lead product Xlucane and announced a sales target for the biosimilar, according to a press release.

Xlucane, a ranibizumab (Lucentis, Novartis/Genentech) biosimilar, is being co-developed and commercialized with Stada Arzneimittel AG, and is expected to bring in revenue during the first quarter of 2022, the release said.

The company has set an annual net sales target of 350 million euros after the product launch.

“We strongly believe in the commercial prospects of Xlucane. There is a great need for more cost-efficient products in the ophthalmic VEGFa inhibitor market and I am confident that Xlucane will be received positively by the ophthalmology community and patients,” Xbrane CEO Martin Åmark said.